Ardelyx Inc Banner Image

Ardelyx Inc

  • Ticker ARDX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Ardelyx Inc Logo Image
  • 51-200 Employees
  • Based in Fremont, California
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndromeMore and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease.
4.8 / 5.0 (148)

Ardelyx Inc reports have an aggregate usefulness score of 4.8 based on 148 reviews.

Ardelyx Inc

Most Recent Annual Report

Ardelyx Inc
MOST RECENT 2022 Annual Report and Form 10K

Ardelyx Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Ardelyx Inc Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!